Search research articles
Contact Us
Filters
Showing results (271-280 of 289) with videos related to
Page
of 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2020
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer
David E Gerber, William C Putnam, Farjana J Fattah, et al.
Cancer Cell
|
December 14, 2016
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors
Xiumei Huang, Edward A Motea, Zachary R Moore, et al.
Journal for Immunotherapy of Cancer
|
June 26, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al.
Biorxiv : the Preprint Server for Biology
|
July 15, 2024
Cmai: Predicting Antigen-Antibody Interactions from Massive Sequencing Data
Bing Song, Kaiwen Wang, Saiyang Na, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2026
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators
Deborah B Doroshow, Ticiana A Leal, Saiama N Waqar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2026
Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators
Deborah B Doroshow, Ticiana A Leal, Saiama N Waqar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
David E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
Nature Cell Biology
|
August 1, 2022
EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation
Gao Guo, Ke Gong, Nicole Beckley, et al.
The New England Journal of Medicine
|
September 29, 2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Hossein Borghaei, Luis Paz-Ares, Leora Horn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
Hossein Borghaei, Scott Gettinger, Everett E Vokes, et al.
Page
of 29
Search research articles
Search
Showing results (271-280 of 289) with videos related to
Sort By:
Page
of 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2020
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer
David E Gerber, William C Putnam, Farjana J Fattah, et al.
Cancer Cell
|
December 14, 2016
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors
Xiumei Huang, Edward A Motea, Zachary R Moore, et al.
Journal for Immunotherapy of Cancer
|
June 26, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al.
Biorxiv : the Preprint Server for Biology
|
July 15, 2024
Cmai: Predicting Antigen-Antibody Interactions from Massive Sequencing Data
Bing Song, Kaiwen Wang, Saiyang Na, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2026
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators
Deborah B Doroshow, Ticiana A Leal, Saiama N Waqar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2026
Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators
Deborah B Doroshow, Ticiana A Leal, Saiama N Waqar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
David E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
Nature Cell Biology
|
August 1, 2022
EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation
Gao Guo, Ke Gong, Nicole Beckley, et al.
The New England Journal of Medicine
|
September 29, 2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Hossein Borghaei, Luis Paz-Ares, Leora Horn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
Hossein Borghaei, Scott Gettinger, Everett E Vokes, et al.
Page
of 29